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Antigenic variation is a characteristic feature of lentiviral infection. The SIV/macaque model of AIDS provides an ideal
system in which to investigate the molecular basis of antigenic variation. The purpose of this study was to genetically map
the nucleotide changes in env that alter the neutralization phenotype of SIV. Serum taken from an SIVmac239-infected
macaque (2D) at 30 weeks postinoculation was found to neutralize the input virus (SIVmac239) and an isolate, P9, obtained
at 10 weeks p.i., but did not neutralize two other isolates, P13 and P23, obtained at 20 and 52 weeks, respectively. Sequence
analysis of these virus variants revealed clustered amino acid changes in V1 and single base pair changes in V2–V4 of
P13 and P23. Infectious recombinant viruses in which the V1 and V1–V3 sequences of SIVmac239 were replaced with those
of P13 or P23 retained the neutralization profile of SIVmac239; both were neutralized by macaque 2D serum. Recombinants
containing the entire surface glycoprotein (gp120) (V1–V5) and the 5* portion of gp41 of P13 and P23 and those containing
gp120 sequences from V4 through the 5* portion of the transmembrane glycoprotein (gp41) were not neutralized by 2D
serum. Using a panel of monoclonal antibodies in radioimmunoprecipitation assays, P23 and recombinants containing V4
and V5 of P23 were shown to be antigenically distinct from P13 and SIVmac239. The majority of the amino acid changes in
the antigenically distinct viruses were clustered in V4 (amino acids 413–418) and these changes created new potential N-
linked glycosylation sites. This study demonstrates that a small number of specific amino acid changes (amino acids 412
to 418 in the env gene) in the V4 region of the SIV envelope glycoprotein can alter antibody recognition and neutralization
and that these phenotypic changes may be associated with altered glycosylation of the envelope. q 1996 Academic Press, Inc.
INTRODUCTION However, viral replication proceeds despite the presence
of neutralizing antibodies and new viral variants continue
Lentiviruses cause lifelong persistent infections in
to evolve (Narayan et al., 1977; Clements et al., 1980;their hosts resulting in chronic progressive disease (Nar-
Narayan et al., 1981). Studies of HIV-1 also suggest thatayan and Clements, 1990). Although immune responses
antigenic variation occurs in the infected individual. Inelicited in lentiviral infections include both neutralizing
vivo studies with viral isolates taken sequentially fromantibodies and cytotoxic T lymphocytes, neither elimi-
HIV-1-infected patients have shown that genetic hetero-nates infection nor halts the progression of disease (Katz
geneity develops over time, whereas soon after initialand Skalka, 1990; Robert-Guroff et al., 1985). Lentiviruses
infection viral heterogeneity is very limited (Hahn et al.,have a high rate of genetic variation due to the lack of
1986; Goodenow et al., 1989; Albert et al., 1990; Sim-proofreading of reverse transcriptase; errors generated
monds et al., 1990). Antigenic variation of HIV-1 has beenby the enzyme during viral replication result in a hetero-
demonstrated in vitro using patient serum to select vi-geneous population of viruses with different biological
ruses with altered neutralization profiles (Robert-Guroffproperties within an individual (Domingo, 1989;
et al., 1986). Whether new variants emerge in vivo inGoodenow et al., 1989; Holland et al., 1992). Antigenic
response to selection pressure from neutralizing antibod-variation allows the virus to replicate and spread in an
ies is not known.immune host, increasing the viral load and the number
In this study the SIV/macaque model was used to ex-of persistently infected cells.
amine the molecular changes that lead to antigenic varia-Antigenic variation has been well documented in both
tion. Infection of a macaque (2D) with SIVmac239 resultedthe equine and the ovine lentiviruses. Infection of horses
in the emergence in vivo of antigenically distinct viruseswith EIAV is characterized by successive episodes of
(Joag et al., 1993). Neutralizing sera from macaque 2Dviremia following the emergence of new antigenic vari-
did not recognize the antigenic variants. Infectious re-ants (Kono, 1988; Montelaro et al., 1984). Visna virus-
combinant clones were constructed by replacing se-infected sheep also produce neutralizing antibodies.
quences of the input virus with those of the antigenic
variants. Amino acids 412 to 418 in the V4 region of the1 To whom correspondence and reprint requests should be ad-
dressed. envelope glycoprotein were found to be important for
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virus neutralization, possibly by altering a glycosylation nies were used to identify colonies containing the con-
structs.site.
Sequence analysis of PCR productsMATERIALS AND METHODS
Three of the Env/pse380 clones from P13 and P23Viruses
were sequenced according to the Sanger dideoxy
SIVmac239 virus variants P9, P13, and P23 were isolated method (Sanger et al., 1977). P13 and P23 sequences
from the sera of macaque 2D by cocultivation of isolated were then compared to the published sequence of
PBMCs with C8166 cells at 10, 20, and 52 weeks p.i., SIVmac239 to identify nucleotide differences (Regier and
respectively. Viral stocks for infectious recombinant vi- Desrosiers, 1990).
ruses were prepared in CEMx174 cells grown in RPMI
1640 media supplemented with 10% fetal bovine serum Construction of infectious recombinant viruses
(Atlanta Biologicals), 10 mg/ml gentamicin (Gibco), and 2
An infectious molecular clone of SIVmac239 (providedmM glutamine (Gibco). Cells were transfected with infec-
by R. Desrosiers, Harvard University) was subcloned intotious DNA by electroporation using the Bio-Rad Gene
pUC19 at the EcoRI site to make p239 which served asPulser with a pulse of 200 V and 960 F. Ten to twenty
the backbone for all of the recombinants shown in Fig.micrograms of each viral clone was used in the transfec-
2. p239 TXN was created to eliminate the second Tth111Itions. After 4 to 7 days, cultures were examine for fusion
site at nt 8571. The env region from the second Tth111Icytopathic effects (CPE). The supernatants from the cul-
site to NheI of SIVmac239 was amplified with an oligonu-tures were collected and virus was titered in CEMx174
cleotide containing a C residue to replace the naturallycells and stored at 0807.
occurring T residue at nt 8569. The new env fragment
carrying a silent mutation at the second Tth111I site wasDNA isolation and PCR
cloned back into p239. To construct the V1 recombinants,
PCR fragments from the Eco47III site to the first Tth111IDNA isolated from C8166 cells infected with viral iso-
lates P9, P13, and P23 was used in polymerase chain site from P13 and P23 were cloned into p239 TXN which
had been digested with Eco47III and Tth111I. SIVmac239reactions (PCRs) to amplify the env region of SIV. The
env PCR products from two or three reactions were se- recombinants containing V1 fragments from P13 and P23
were constructed by overlapping PCR. Primers 481 (seequenced by one of two methods. In method 1, the PCR
products were precipitated with 0.6 volumes of 20% poly- DNA isolation and PCR section for sequence) and 480
(5*-CACTTAAAACAAGATCGCGATAAGCA-3*) were usedethylene glycol and 2.5 M NaCl and sequenced by the
Sanger dideoxy method (Sanger et al., 1977) using 32P- to amplify SIVmac239 sequences from nt 6599 to nt 6908.
P13 and P23 sequences from nt 6882 to 7303 were ampli-end-labeled primers. In method 2, PCR env products
were gel purified and sequenced by the Applied Biosys- fied with primers 479 (5*-TGCTTATCGCGATCTTGCTTT-
TAAGTG-3*) and 482 (5*-AAGCTTGAATTCAGTCTCATT-tems automated sequencer Model 373A. P9 and P13 env
sequences were sequenced by method 1 and P23 env GACCATGTCTAC-3*). Primer 482 includes an EcoRI site
for cloning. Two microliters of the 6599 to 6908 productsequences were sequenced by method 2. To confirm the
sequences obtained for the antigenic variants P13 and from SIVmac239 and 2 ml of the 6882 to 7303 product
from either P13 or P23 were combined in separate PCRP23 a second infection and DNA isolation were done.
CEMx174 cells infected with viral isolates P13 and P23 reactions for a second round of (overlapping) amplifica-
tion with outside primers 481 and 482. The products werewere lysed and phenol/chloroform extracted. DNA (1 mg)
from each sample was used in multiple PCRs to amplify digested with EcoRI and BamHI, cloned into pUC19, and
sequenced to determine if the sequence was correct.the env region from nucleotide 6599 to 9040 using the
following primers derived from the nucleotide sequence These constructs were digested with Eco47III and
Tth111I and cloned into p239TXN.of SIVmac239: 481, 5*-AAGCTTGGATCCCTCCAACGA-
GCGCTCTTCAT-3* and 702, 5*-TGAGGATCCGAAGAG- To construct the V1–V5, V1–V3, and V4–V5 recombi-
nants, env/pse380 clones from both P13 and P23 wereAACACTGGCCTATACCC-3*. Primer 481 includes a
BamHI site for cloning. The sequences amplified in- cut at the Eco47III and NheI sites to yield the 2.4-kb
env fragment. A portion of this DNA was used in a thirdcluded V1–V5 and 570 nucleotides of the transmem-
brane. The 2.4-kb PCR products were then cloned into restriction digest with MroI approximately 1.4 kb down-
stream of the Eco47III site, yielding 1.4- and 1-kb frag-pse380 (Invitrogen) at Eco47III and NheI restriction sites.
The env fragment from 6607–9000 in pse380 is called ments. To replace analogous sequences in SIVmac239,
p239 was cut with different pairs of the same three en-Env/pse380. Both restriction sites are unique sites in the
env gene of SIVmac239 and the variants. The Env/pse380 zymes: Eco47III/NheI to remove a 2.4-kb fragment,
Eco47III/MroI to remove a 1.4-kb fragment, and MroI/constructs from P13 and P23 were electroporated in
GM2163 (dam0 and dcm0; New England Biolabs) cells. NheI to remove a 1-kb fragment. The digested p239 ‘‘vec-
tors’’ were ligated to the corresponding fragments fromRestriction digests on DNA isolated from bacterial colo-
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the envelope clones of P13 and P23 (Fig. 2). The recombi- sulted in nine amino acid substitutions. Five of these
were clustered near the amino terminus; the changesnants were then sequenced to verify that the sequences
of p239 had been replaced by analogous sequences from were valine at position 67 to methionine (V67M), S105A,
I127V, T134I, and A140T. The other changes were in V3the variants and that all the ligations had occurred cor-
rectly. (K340R), in V4 (A417T), between V5 and the gp120–gp41
cleavage site (D511G), and in gp41 (L606V) (Fig. 1). Se-
Neutralization assays quence analysis of P23 (isolated 52 weeks p.i.) revealed
3 mutations in common with P13 (V67M, I127V, andPlasma isolated from the SIVmac239-infected macaque A417T) and 16 additional mutations in env (Fig. 1). P232D (Joag et al., 1993) at 30 weeks p.i. was serially diluted
had additional amino acid changes clustered in thetwo- or fivefold with RPMI/10% FBS in 96-well plates.
amino terminus of env-V67M, K103R, I127V, T134A,All dilutions were done in quadruplicate; the assay was
T136A, and K141E.performed in duplicate. Fifty microliters of diluted virus
Virus isolate P13 had a new glycosylation site at amino(between 5 and 10 TCID50) was added to each quadrupli- acid 415 (amino acids NTT) and P23 had two new glyco-cate well. After incubating the plates at 377 for 1 hr, 100
sylation sites at amino acids 254 (amino acids NCS) and
ml of 1 1 105 indicator cells (CEMx174) were added to
413 (amino acids NRS). Two of the new potential glyco-each well. Each dilution of virus was incubated in RPMI/
sylation sites, 415 and 413, are located in the V4 region10% FBS media with CEMx174 cells to control for the
of the surface glycoprotein.amount of virus in the neutralization assay. Plates were
scored for the presence of virus-induced CPE after 7 to
Analysis of the envelope proteins of SIVmac239 and10 days as previously described (Clements et al., 1994).
antigenic variants
Immunoprecipitation of virus proteins To determine whether the amino acid changes in the
antigenic variants resulted in altered recognition byCEMx174 cells (5 1 106) were infected with p239, P13,
monoclonal antibodies specific for the SIV envelope gly-P23, and all six recombinant viruses. After approximately
coprotein, three monoclonal antibodies, KK9, KK13 and1 week, infected cultures and a mock-infected control
KK54, were used to immunoprecipitate the gp120 proteinculture were incubated with L-[35S]methionine–cysteine
from [35S]methionine-labeled cell lysates prepared from(35S-Translabel; Du Pont NEN Products, Boston, MA) for
CEMx174 cells infected with SIVmac239, P13, and P23.6 hr. 35S-labeled cells were lysed and counted, and 1 1
KK13 and KK54 mapped to epitopes in the V2 envelope106 cpm was used in each immunoprecipitation assay
region of SIV. However, the epitope that monoclonal anti-with 5 ml of each monoclonal antibody (KK9,KK13, and
body KK9 recognizes is unknown (Kent et al., 1992).KK54 were kindly provided by Dr. Karen Kent) as de-
Monoclonal antibodies KK54 and KK9 have been shownscribed (McEntee et al., 1992). Protein G–Sepharose
to have neutralizing activity against SIV (Kent et al., 1992).beads were used to precipitate antibody–gp120 com-
Both KK13 and KK54 recognized the gp120 protein fromplexes. The precipitated proteins were separated by
the cell lysates of SIVmac239, P13, and P23 (data notSDS–PAGE, and the gels were treated with Entensify,
shown). In contrast, KK9 could distinguish changes in thedried, and exposed to X-ray film at 0707.
viral envelope proteins and recognized only the gp120
protein from SIVmac239 and P13 cell lysates (Fig. 3). KK9RESULTS
monoclonal antibody was found to neutralize only P23
Nucleotide sequence analyses of the env gene of and not SIVmac239 or P13 (Table 1). Thus, changes in P23
antigenically distinct viruses apparently made it susceptible to neutralization by KK9.
However, KK9 did not recognize the gp120 protein from
To identify nucleotide changes between the input virus
P23 in immunoprecipitation assays, this may be due to
SIVmac239 and the antigenic variant viruses, the env the additional amino acid changes in the Env protein of
genes of the isolates P9, P13, and P23 were sequenced
P23 compared to P13 that may have altered the confor-
(Fig. 1). The regions of the envelope glycoprotein have
mation of the protein.
been labeled variable regions 1–5 (V1–V5) by analogy
to HIV-1 (Burns and Desrosiers, 1991). Virus P9, isolated Construction of infectious recombinant viruses
10 weeks p.i., prior to detection of neutralizing antibodies containing portions of the env genes
(112 days p.i.), had the neutralization profile of SIVmac239 of the antigenic variants
(Table 1) and had only a single nucleotide change com-
pared to SIVmac239 (Fig. 1). In contrast, P13 isolated 20 Recombinant viruses were constructed using the
backbone of SIVmac239 and portions of the env genes ofweeks p.i., after the neutralizing antibodies were de-
tected, was not neutralized by sera that neutralized both the antigenic variants P13 and P23 (Fig. 2). When the V1
region of the env gene of SIVmac239 was replaced withSIVmac239 and P9 (Table 1). Sequence analysis of P13
revealed that the mutation found in P9 was not present the V1 region of P13 or P23, the recombinant viruses
retained the neutralization profile of SIVmac239 (Table 1).in P13. However, other nucleotide changes in P13 re-
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FIG. 1. Amino acid comparison of SIVmac239 and variants P9, P13, and P23 isolated from macaque 2D. The amino acid sequence (1 to 730) for
the Env protein of SIVmac239 (Burns and Desrosiers, 1991) is shown with the location of the variable regions from HIV-1 and the putative proteolytic
cleavage site. Amino acids in the variants that are identical to amino acids in SIVmac239 are indicated by a dash, and different amino acids are
indicated by the one-letter abbreviation of the new amino acid. An asterisk indicates a silent mutation.
These results indicate that the V1 region of viruses P13 P13 and P23. Both of the EM recombinants were neutral-
ized by 2D sera; they retained the neutralization pheno-and P23 does not contain determinants for neutralization.
Recombinants SIVmac239/13 EN and SIVmac239/23EN type of SIVmac239. In contrast, the MN recombinants con-
taining regions V4 and V5 from the variant viruses werecontaining V1–V5 and a portion of gp41 from P13 and
P23 inserted into the backbone of SIVmac239 had the not neutralized.
neutralization profile of the variants P13 and P23, not
SIVmac239. Serum taken from macaque 2D at 30 weeks Analysis of the envelope proteins of the recombinant
postinoculation that neutralized SIVmac239 did not neu- viruses
tralize SIVmac239/13EN or SIVmac239/23EN. Thus, amino
acid changes within the V1–V5 regions of P13 and P23 SIVmac239, P13, and P23 were tested in radioimmuno-
precipitation assays with a panel of monoclonal antibod-were responsible for escape from neutralization. To fur-
ther localize the mutations responsible for these biologi- ies. Monoclonal antibody KK9 was able to distinguish
virus P23 from SIVmac239 and variant P13 (Fig. 3). Tocal changes, additional recombinants were con-
structed—SIVmac239/13EM, SIVmac239/23EM, SIVmac239/ localize the region of P13 that was recognized by KK9
and that differentiated this variant from P23, the viral13MN, and SIVmac239/23MN—containing different por-
tions of the V1–V5 regions in the background of recombinants were tested against KK9 in radioimmuno-
precipitation assays with labeled cell lysates preparedSIVmac239 (Fig. 2). The EM recombinants were con-
structed by replacing SIVmac239 sequences from Eco47III from CEMx174 cells infected with SIVmac239, P13, P23,
and all six recombinants. The gp120 from lysates of cells(nt 6607) to MroI (nt 8016) with analogous sequences
from P13 and P23 (Fig. 2). These recombinants contained infected with SIVmac239, P13, and all SIVmac239/13 recom-
binants were recognized by KK9 (Fig. 4). In addition,the V1 to V3 regions of the variants. The MN constructs
were generated in a similar manner except that SIV- SIVmac239/23EM which contains V1–V3 from P23 and
V4–V5 from SIVmac239 was immunoprecipitated (Fig. 4).mac239 sequences from MroI (nt 8016) to NheI (nt 9000)
were replaced by analogous sequences from the vari- However, KK9 did not recognize P23, SIVmac239/23EN,
nor SIVmac239/23MN. These results suggest either thatants. These sequences include the V4 to V5 regions of
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TABLE 1 changes in V4. This suggests that KK9 neutralizes SIV
by interaction with an epitope in V4. Neutralization via
this epitope is likely to be conformationally dependent
Neutralization titera because KK9 did not immunoprecipitate the denatured
SU protein of P23.
Viruses and Macaque In other lentiviral systems, antigenic variation plays an
recombinants 2D sera KK9 Mab
important role in the manifestation of periodic episodes
of clinical disease and viral persistence. Studies by KonoViruses
SIVmac239 2.3 0.0 et al. demonstrated antigenic variation in EIAV infections
P9 2.3 0.0 and showed that emergence of new viral strains was
P13 0.0 0.0 followed by exacerbation of disease. Sequential isolates
P23 0.0 1.2
taken from infected animals during clinical episodesRecombinants
were found to be antigenically distinct from previous iso-SIVmac239/13-V1 2.8 NDb
SIVmac239/23-V1 2.4 ND lates (Kono et al., 1973). The molecular basis of antigenic
SIVmac239/13EN 0.50 ND variation in EIAV has been shown to be point mutations
SIVmac239/23EN 0.58 ND in the variable regions of the env gene that alter viral
SIVmac239/13EM 2.80 ND
antigenicity (Payne et al., 1989; Montelaro et al., 1984).SIVmac239/23EM 2.91 ND
In studies of visna virus-infected sheep, antigenic vari-SIVmac239/13MN 0.80 ND
SIVmac239/23MN 1.05 ND ants have been isolated in the presence of neutralizing
antibodies (Narayan et al., 1977a,b; Griffin et al., 1978;
a 50% neutralization titer is expressed as the reciprocal of the 50% Gudnadottir, 1974). However, antigenic variation occurs
neutralization end point (log10). Neutralizing titer is representative of at at a low level, and the antigenic variants do not replaceleast two independent assays.
the original virus strain. Thus in contrast to EIAV infection,b ND, not done.
antigenic variation is not necessary for viral persistence
or continued viral replication in sheep (Clements et al.,
KK9 binds an epitope within the V4–V5 region of SIV- 1988). As in EIAV, differences in antigenicity of the anti-
mac239 and P13 or that changes in that region affect the genic variants were attributed to point mutations in the
binding of this monoclonal antibody to another epitope. env gene (Clements et al., 1980).
There are four amino acid differences between P13 Others have also identified the V4 region as an im-
and P23 in this region. P13 had one amino acid change portant determinant for neutralization of SIVmac . Choi et
(A417T) which results in a new glycosylation site (NTT). al. found that sequence changes in V4 were involved in
P23 has four amino acid changes (D413N, N415S, A417T, escape from neutralization of naturally occurring variants
and N418D), and one of the changes (N415S) is involved of SIVmac239 (Choi et al., 1994). In addition, a protease
in creating a new glycosylation site (NRS). digestion fragment of the SIV SU glycoprotein containing
the V4 region was shown to block neutralizing antibodies
in sera from a macaque infected with SIVmac251 (Javaher-DISCUSSION
ian et al., 1992). Amino acids 410 to 430 of the V4 region
have been found to contain a neutralization epitope (Tor-Antigenic variation is characteristic of lentiviral infec-
tions. In this study, the molecular changes that occurred res et al., 1993). However, SIVmac neutralization epitopes
have also been identified in the V2 region of the SUduring natural antigenic variation were identified and
found to map to the V4 region of the surface (SU) glyco- protein and in the transmembrane glycoprotein. Neu-
tralizing monoclonal antibodies directed against SIVmacprotein. Infectious recombinant viruses were constructed
with regions of the SU glycoprotein of two antigenic vari- were shown to bind to amino acids and conformational
epitopes in the V2 region (Kent et al., 1992; Benichou etants of SIVmac239 (P13 and P23), but changes in the V4
region altered the neutralization phenotype of these vi- al., 1992). The transmembrane protein contains a neutral-
ization epitope in a variable region between amino acidsruses when tested with sera from the macaque in which
the antigenic selection occurred. This is the first study 106 and 110. This neutralizing determinant has also been
found in HIV-1 and HIV-2 (Kodama et al., 1991).to show that specific amino acid changes in V4 are asso-
ciated with neutralization by antibodies from infected ma- Previously, the V3 region of HIV-1 was thought to be the
major neutralization determinant (Ho et al., 1987; Goudsmitcaques. Both mutant viruses had a limited number of
sequence changes in V4. P13 had a single amino acid et al., 1988; Matsushita et al., 1988; Skinner et al., 1988;
Javaherian et al., 1990; Broliden et al., 1992), but other re-change that conferred the altered phenotype. These
changes created new glycosylation sites in both viruses, gions are now recognized as being important determinants
of neutralization. V2, V5, and conserved regions have allsuggesting that glycosylation may have contributed to
the ability of the variants to escape neutralization. In been shown to contain epitopes that induce neutralizing
antibodies (Fung et al., 1992; Ho et al., 1987, 1988; Brolidenaddition, it was found that monoclonal antibody KK9 neu-
tralized only P23 containing the most amino acid et al., 1992; Gnann et al., 1987; Chanh et al., 1986). The
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FIG. 2. SIVmac239 recombinant viruses containing 2D variant P13 or P23 envelope sequences. A schematic of the SIVmac239 genome is shown
with the open reading frames. Sequences for the viral proteins Tat and Rev are indicated below the schematic, and Env sequences with the variable
regions (V1 – V5) and the putative SU/transmembrane cleavage site are shown. The SIVmac239/2D recombinants are shown with the restriction sites
used to construct the recombinants. Below is the SIVmac239 sequence from nucleotide 6560 to 9000. Cross-hatched boxes represent sequences
from the 2D variants (P13 or P23) and open boxes represent sequences from SIVmac239.
analogous V3 region of SIV, however, contains a conserved of proteins (Fenouillet and Gluckman, 1991; Li et al.,
1993), and changes in glycosylation have been shown,region that has not been associated with neutralization
(Burns and Desrosiers, 1991). in other lentiviruses, to alter neutralization. Caprine ar-
thritis–encephalitis virus induces the production of littleEscape from neutralization of variants P13 and P23
was shown to be associated with the appearance of or no neutralizing antibody in the infected animals. Re-
moval of N-linked carbohydrates from the surface bynew potential N-linked glycosylation sites. Alteration of
glycosylation patterns is known to alter the conformation neuraminidase, however, renders the virus highly neu-
FIG. 3. Immunoprecipitation of gp120 of SIVmac239, P13, and P23 with monoclonal antibodies KK9, KK13, and KK54. CEMx174 cells infected with
the indicated virus were labeled with [35S]methionine–cysteine and immunoprecipitation was done as described under Materials and Methods.
Marker molecular weights are indicated by arrows and gp120 bands are indicated by an asterisk. (A) Lanes a and e, gp120 from P23 cell lysates;
lanes b and f, gp120 from P13 cell lysates; lanes c and g, gp120 from SIVmac239 cell lysates; lanes d and h, mock-infected cell lysates. Lanes a
through d were precipitated with KK9 and lanes e through h were precipitated with KK13. (B) Lane a, gp120 from P23 cell lysates; lane b, gp120
from P13 cell lysates; lane c, gp120 from SIVmac239 cell lysates; lane d, mock-infected cell lysates. Lanes a through d were precipitated by KK54.
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